New England Journal of Medicine highlights long-term success of Sana's insulin cell therapy for type 1 diabetes without immunosuppression
Sana Biotechnology announced that The New England Journal of Medicine published a letter detailing 14-month positive follow-up data from a study on their hypoimmune (HIP)-modified islet cell therapy for type 1 diabetes. The therapy showed safety, imm...
